Literature DB >> 8807662

Genetic polymorphisms of debrisoquine and S-mephenytoin oxidation metabolism in Chinese populations: a meta-analysis.

H G Xie1, Z H Xu, X Luo, S L Huang, F D Zeng, H H Zhou.   

Abstract

Chinese data on the polymorphic metabolism of debrisoquine, metoprolol, codeine and mephenytoin were collected and re-analysed using a meta-analysis method. There were no significant differences in the incidences of poor metabolizer (PM) between the separate series of debrisoquine, metoprolol and codeine, which are the three probe drugs reflecting the same enzyme polymorphism. PMs were detected at low frequencies for debrisoquine (1.20%; 95% confidence interval, CI: 0.67-1.98%), metoprolol (0.72%; CI: 0.29-1.49%) and codeine (0.48%, CI: 0.01-2.68%). The overall estimate of PM was 0.95% (CI: 0.60-1.42%) based on the 2427 determinations of all three probe drugs. The overall mean of PM of mephenytoin was 14.32% (12.26-16.38%) in the 1117 subjects. In summary, the present meta-analysis determined the accurate incidences of the genetic deficiency of S-mephenytoin 4'-hydroxylase (cytochrome P450 2C19) and debrisoquine hydroxylase (cytochrome P450 2D6) in Chinese populations.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8807662     DOI: 10.1097/00008571-199606000-00005

Source DB:  PubMed          Journal:  Pharmacogenetics        ISSN: 0960-314X


  2 in total

1.  Ethnic-specific in vitro-in vivo extrapolation and physiologically based pharmacokinetic approaches to predict cytochrome P450-mediated pharmacokinetics in the Chinese population: opportunities and challenges.

Authors:  Guo-Fu Li; Guo Yu; Hong-Xia Liu; Qing-Shan Zheng
Journal:  Clin Pharmacokinet       Date:  2014-02       Impact factor: 6.447

2.  Genetic polymorphism of (S)-mephenytoin 4'-hydroxylation in populations of African descent.

Authors:  H G Xie; R B Kim; C M Stein; G R Wilkinson; A J Wood
Journal:  Br J Clin Pharmacol       Date:  1999-09       Impact factor: 4.335

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.